On August 6, 2025, ESSA Pharma announced a capital distribution of $80 million to shareholders in connection with its merger with XenoTherapeutics, following court approval on August 5, 2025, expecting to pay around $1.91 per share on August 22, 2025. A special shareholder meeting to approve the merger is set for September 10, 2025.